Prostate cancer: screening is recommended in the US – now it’s time for Italia to follow suit
The American experts’ guidelines are straightforward: a PSA test every two years, from the ages of 50 to 69, for men at moderate risk
The American Cancer Society’s new guidelines on the early diagnosis of prostate cancer mark a shift in approach that, as urologists, we have long been awaiting. For sixteen years, the message had essentially been, ‘discuss it with your doctor and decide together’. Today, one of the world’s most authoritative scientific societies clearly states that the benefits of PSA screening outweigh the risks, and recommends it.
The guidance is straightforward: a PSA test every two years, from the ages of 50 to 69, for men at moderate risk. Those at higher risk – starting with those whose father or brother has had the disease – should begin at the age of 45 and, in some cases, repeat the test every year. Between the ages of 70 and 74, the decision should be assessed on a case-by-case basis; from the age of 75, screening is no longer recommended.
Two things have changed. The first is that we now have more robust data: the large-scale European ERSPC study, after 23 years of observation, has shown that screening reduces deaths from prostate cancer and that the benefit increases over time. There is also a reduction in the number of cases detected when the disease has already spread – that is, those that are the most difficult to treat. The second is that we have learnt to minimise the side effects that for years held back screening: too many biopsies and too many treatments for cancers that would never have caused any problems.
Nowadays, a high PSA level does not automatically lead to a biopsy. The test is repeated and, if the level remains high, an MRI scan or other tests are carried out to help determine who really needs further investigation. And when a low-risk tumour is found, the first choice is not surgery but active surveillance: regular check-ups, and treatment only if and when necessary. There is also an important new development: the American guidelines make it clear that a digital rectal examination is not recommended as a screening test. A blood test is all that’s needed. This removes one of the barriers – including psychological ones – that keep many men from seeking preventive care.
Of course, these are recommendations designed for the US context, and not everything can be applied directly to our country. However, the direction is the same as that set out by the European Union, which, from 2022, is calling on Member States to consider organised prostate screening programmes. And the American experts themselves point out that these recommendations only work if healthcare systems invest in organised programmes capable of supporting individuals from their first screening right through to any further investigations.

